• Jun Wang, Elizabeth A Mittendorf, Aysegul A Sahin, Min Yi, Abigail Caudle, Kelly K Hunt, and Yun Wu.
• Department of Oncology, General Hospital, Jinan Command of People's Liberation Army, Jinan, China ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
• Plos One. 2014 Jan 1; 9 (2): e89778.

BackgroundThe American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in local-regional recurrence (LRR), disease-specific survival (DSS) or overall survival (OS) for sentinel lymph node dissection (SLND) and completion axillary lymph node dissection (ALND) among patients undergoing breast-conserving therapy for clinical T1-T2, N0 breast cancer with 1 or 2 positive SLNs. However, Only 7% of study participants had invasive lobular carcinoma (ILC). Because ILC has a different pattern of metastases, frequently presenting as small foci requiring immunohistochemistry for detection, the applicability of ACOSOG Z0011 trial data to ILC patients is unclear.Study DesignWe identified all ILC patients in the Surveillance, Epidemiology, and End Results (SEER) database (1998-2009) who met the ACOSOG Z0011 eligibility criteria. Patients were evaluated on the basis of the extent of axillary surgery (SLND alone or ALND), and the clinical outcomes of these 2 groups were compared.Results1269 patients (393 SLND and 876 ALND) were identified from the SEER database. At a median follow-up time of 71 months, there were no differences in OS or disease-specific survival between the two groups.ConclusionSLND alone may result in outcomes comparable to those achieved with ALND for patients with early-stage ILC who meet the ACOSOG Z0011 eligibility criteria.

20 keywords...

hide…